ATP5F1D: A Promising Target for Neurological & Psychiatric Disorders

Target Name: ATP5F1D

NCBI ID: G513

ATP5F1D

ATP5F1D: A Promising Target for Neurological & Psychiatric Disorders

ATP5F1D is a gene that encodes for a protein known as ATP5F1D. This protein is a key player in the regulation of the blood-brain barrier, which is responsible for controlling the movement of nutrients, drugs, and other substances into and out of the brain.

Research has shown that ATP5F1D plays a crucial role in maintaining the integrity of the blood-brain barrier. This is important for maintaining the health and function of the brain, as the barrier helps to protect the brain from harmful substances and prevent it from becoming inflamed or damaged.

Mutations in the ATP5F1D gene have been linked to a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This suggests that ATP5F1D may be an important drug target or biomarker for these conditions.

One way to target ATP5F1D is through the use of small molecules, such as drugs that can modulate the activity of the protein. Researchers have identified a number of potential small molecules that have been shown to interact with ATP5F1D and are being tested for their potential as treatments for neurological and psychiatric disorders.

Another approach to targeting ATP5F1D is through the use of antibodies, which are proteins that recognize and bind to specific molecules on the surface of cells. Researchers have developed antibodies that are designed to recognize and bind to ATP5F1D and are being tested as potential treatments for neurological and psychiatric disorders.

In addition to its potential as a drug target or biomarker, ATP5F1D is also of interest to researchers because of its role in the regulation of the blood-brain barrier. This is an important topic because the blood-brain barrier is a complex system that is difficult to study, and understanding its regulation is important for developing new treatments for neurological and psychiatric disorders.

Overall, the research on ATP5F1D is still in its early stages, but it is an promising area of study that has the potential to lead to new treatments for neurological and psychiatric disorders. Further research is needed to fully understand the role of ATP5F1D in the regulation of the blood-brain barrier and to identify effective small molecules and antibodies that can modulate its activity.

Protein Name: ATP Synthase F1 Subunit Delta

Functions: Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (PubMed:29478781). F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP turnover in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation. Part of the complex F(1) domain and of the central stalk which is part of the complex rotary element. Rotation of the central stalk against the surrounding alpha(3)beta(3) subunits leads to hydrolysis of ATP in three separate catalytic sites on the beta subunits (PubMed:1531933)

The "ATP5F1D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP5F1D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets